![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
EB Haddad, JC Mak and PJ Barnes
Department of Thoracic Medicine, National Heart and Lung Institute, London, UK.
Ba 679 BR [7(S)-(1 alpha, 2 beta, 4 beta, 5 alpha, 7 beta)-7- [(hydroxydi(2-thienyl) acetyl)oxy]-9,9-dimethyl-3-oxa-9- azoniatricyclo[3.3.1.0(2,4)]nonan e bromide] is a new long-acting muscarinic antagonist developed as a bronchodilator drug. In this study, we have evaluated its affinity, its selectively, and the distribution of its binding sites in human lung. [3H]Ba 679 BR binds to a homogeneous population of muscarinic receptors in human lung membranes, with affinities in the subnanomolar concentration range. Like ipratropium bromide, Ba 679 BR showed no selectivity in its interactions with rat cerebrocortical M1 receptors (labeled with [3H]telenzepine) or heart M2 and salivary gland M3 receptors [labeled with [N-methyl-3H]scopolamine ([3H)]. Ba 679 BR displayed 6-20-fold higher affinity, compared with ipratropium bromide. We also studied the rate of Ba 679 BR and ipratropium bromide dissociation from human lung muscarinic receptors, by monitoring [3H]NMS association. Unlike ipratropium bromide (100 nM), which dissociated so quickly that there was little difference in the [3H]NMS association, compared with vehicle- treated membranes, Ba 679 BR (1 nM) had a strong protective effect against [3H]NMS binding ( > 70%) that lasted for 90 min. Kinetic experiments conducted with [3H]Ba 679 BR confirmed the slow dissociation profile of this compound. The dissociation rate constant (k-1) for [3H]Ba 679 BR was 3.29 +/- 0.18 x 10(-3) min-1, corresponding to a half-life of the complex of 212 +/- 11 min. Autoradiographic studies revealed that [3H]Ba 679 BR binding sites were densely distributed in alveolar walls and submucosal glands. These results suggest that the slow dissociation profile of Ba 679 BR from human lung muscarinic receptors might be the underlying mechanism by which this drug achieves its long duration of action observed in functional tests.
This article has been cited by other articles:
|
|
 |
|
  P. T. Diaz, A. S. Bruns, M. E. Ezzie, N. Marchetti, and B. M. Thomashow Optimizing Bronchodilator Therapy in Emphysema Proceedings of the ATS, May 1, 2008; 5(4): 501 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R G Barr, J Bourbeau, C A Camargo, and F S F Ram Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax, October 1, 2006; 61(10): 854 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes Distribution of Receptor Targets in the Lung Proceedings of the ATS, December 1, 2004; 1(4): 345 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Gross Tiotropium Bromide Chest, December 1, 2004; 126(6): 1946 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. L. Walker, R. R. Gainetdinov, D. S. Feldman, P. K. McFawn, M. G. Caron, R. J. Lefkowitz, R. T. Premont, and J. T. Fisher G protein-coupled receptor kinase 5 regulates airway responses induced by muscarinic receptor activation Am J Physiol Lung Cell Mol Physiol, February 1, 2004; 286(2): L312 - L319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.-B. Haddad, A. J. Fox, J. Rousell, G. Burgess, P. McIntyre, P. J. Barnes, and K. F. Chung Post-Transcriptional Regulation of Bradykinin B1 and B2 Receptor Gene Expression in Human Lung Fibroblasts by Tumor Necrosis Factor-alpha : Modulation by Dexamethasone Mol. Pharmacol., June 1, 2000; 57(6): 1123 - 1131. [Abstract] [Full Text]
|
|
|
|
|
|
P. J. Barnes The Pharmacological Properties of Tiotropium Chest, February 1, 2000; 117(2_suppl): 63S - 66S. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
